Risk for serious infection substantially higher in pediatric IBDJuly 25, 2021IBD & Intestinal Disorders
IBD: Vedolizumab effective as a steroid-sparing agent among elderlyJuly 25, 2021IBD & Intestinal Disorders
Superior histological outcomes with vedolizumab vs adalimumab in ulcerative colitisJuly 25, 2021IBD & Intestinal Disorders
Infliximab de-escalation safe in patients with Crohn’s disease in clinical remissionJuly 25, 2021IBD & Intestinal Disorders
Benefits of COVID-19 vaccination outweigh risks in patients with IBDJuly 25, 2021IBD & Intestinal Disorders
No adverse impact of infliximab biosimilar switch on IBD control or drug levelsJuly 25, 2021IBD & Intestinal Disorders
Tofacitinib salvage therapy shows promise in patients hospitalized with refractory severe ulcerative colitisJuly 25, 2021IBD & Intestinal Disorders
BNT162b2 mRNA COVID-19 vaccine shows excellent efficacy in patients with IBDJuly 25, 2021IBD & Intestinal Disorders
Adalimumab shows promise in pediatric patients with moderate-to-severe ulcerative colitisJuly 25, 2021IBD & Intestinal Disorders
Anti-TNF therapy increases risk for herpes zoster in patients with IBDJune 24, 2021IBD & Intestinal Disorders
Obesity tied to early readmission risk in patients hospitalized with IBDJune 24, 2021IBD & Intestinal Disorders
Hyperbaric oxygen therapy safe and effective in various IBD phenotypesJune 24, 2021IBD & Intestinal Disorders
Multiple switches from infliximab to biosimilars effective and safe in IBDJune 24, 2021IBD & Intestinal Disorders
